ALMS - Alumis Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$39.33
DETAILS
HIGH:
$51.00
LOW:
$25.00
MEDIAN:
$39.00
CONSENSUS:
$39.33
UPSIDE:
78.61%
About Alumis Inc. Common Stock (https://www.alumis.com)
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Martin Babler | President, Chief Executive Officer & Chairman | 1965 | $1,205,069 USD |
| David Goldstein | Chief Scientific Officer | 1966 | $821,186 USD |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 1965 | $817,058 USD |
| Roy C. Hardiman | Chief Business & Strategy Officer | 1960 | $619,841 USD |
| Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | – | – |
| Grace Halteh | Senior Vice President & Head of Quality and Regulatory | – | – |
| Jack Danilkowicz | Chief Commercial Officer | – | – |
| John R. Schroer | Chief Financial Officer | 1965 | – |
| Kolbot By | Senior Vice President & Head of Technical Operations | – | – |
| Mark Bradley | Chief Development Officer | 1966 | – |
| Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | – | – |
| Sanam Pangali | Chief Legal Officer & Corporate Secretary | 1984 | – |